## CLAIMS

**What is claimed is:**

**1.** A modified oligonucleotide complementary to a portion of a Hepatitis B virus (HBV) genome, wherein the modified oligonucleotide comprises SEQ ID NO: 456.

**2.** The modified oligonucleotide of claim 1, wherein at least one internucleoside linkage is a phosphodiester linkage.

**3.** The modified oligonucleotide of claim 1, wherein at least one internucleoside linkage is a modified internucleoside linkage.

**4.** The modified oligonucleotide of claim 3, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

**5.** The modified oligonucleotide of claim 1, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

**6.** The modified oligonucleotide of claim 1, wherein the modified oligonucleotide is linked to a conjugate group.

**7.** The modified oligonucleotide of claim 1, wherein the modified oligonucleotide is linked to a stabilizing group.

**8.** The modified oligonucleotide of any one of claims 1-7 for use in therapy.

**9.** A pharmaceutical composition comprising the compound of any one of claims 1 to 7, or salt thereof and at least one pharmaceutically acceptable carrier or diluent.

**10.** A formulation comprising about 100 mg/mL, 150 mg/mL, or 200 mg/mL of the modified oligonucleotide of any one of claims 1-7.

**11.** Use of the modified oligonucleotide of any one of claims 1-7 in the manufacture of a pharmaceutical composition for reducing HBV mRNA, HBV DNA, HBV protein, or HBV antigen levels in a subject.

**12.** The use of claim 11, wherein the HBV antigen is HBsAg or HBeAg.

**13.** Use of the modified oligonucleotide of any one of claims 1-7 in the manufacture of a pharmaceutical composition for preventing, treating, ameliorating or slowing the progression of a HBV-related disease, disorder or condition in a subject.

**14.** Use of the modified oligonucleotide of any one of claims 1-7 in the manufacture of a pharmaceutical composition for reducing liver toxicity and/or persistence in a subject having a HBV related disease, disorder or condition.

**15.** The use of any one of claims 11-14, wherein the subject is to be administered with at least one, at least 2, at least 3, at least 4 or at least 5 doses of the pharmaceutical composition.

**16.** The use of any one of claims 11-14, wherein the subject is to be dosed with the pharmaceutical composition on Day 1, Day 4 and Day 8.

**17.** The use of claim 16, wherein the subject is to be dosed with the pharmaceutical composition once every week after Day 8.

**18.** The use of claim 16, wherein the amount of each dose is substantially the same amount.

**19.** The use of claim 17, wherein the amount of each dose is substantially the same amount.

**20.** The use of any one of claims 11-14, wherein the dose of the pharmaceutical composition is 30 mg to 600 mg.

**21.** The use of claim 20, wherein the dose of the pharmaceutical composition is 100 mg to 500 mg

**22.** The use of claim 21, wherein the dose of the pharmaceutical composition is 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 450 mg, or 500 mg.

**23.** The use of any one of claims 11-14, wherein the pharmaceutical composition is to be administered parenterally, subcutaneously, transdermally, intraocularly, intramuscularly, or intravenously.

**24.** The use of any one of claims 11-14, wherein the pharmaceutical composition is to be administered in combination with a second agent.

**25.** The use of claim 13 or 14, wherein the disease, disorder or condition is a liver disease, disorder or condition.

**26.** The use of claim 25, wherein:

a) the disease, disorder or condition is jaundice, liver inflammation, liver fibrosis, inflammation, liver cirrhosis, liver failure, diffuse hepatocellular inflammatory disease, hemophagocytic syndrome, serum hepatitis, HBV infection, HBV viremia, or liver disease-related transplantation; or

b) the disease or condition is a hyperproliferative condition.

**27.** The use of claim 26, wherein the hyperproliferative condition is liver cancer.

**28.** The use of any one of claims 11-14, wherein the subject is co-infected with hepatitis delta virus infection (HDV) and HBV.

**29.** The use of any one of claims 11-14, wherein the subject is human.